Milan, Italy, October 6, 2026 – CPHI Milan 2026, the World’s leading exhibition for Pharmaceutical Ingredients, opened today at Fiera Milano. Wu Xing, Director and Vice President of Hengdian Group, and Brian Zhu, Assistant President of Hengdian Group and Chairman & CEO of Apeloa Pharmaceutical, led the BD team to Milan (Booth No. 7D50) to showcase Apeloa’s integrated pharmaceutical solutions across its three core business segments—CDMO, APIs and FDF—and to discuss industry trends and partnership opportunities with global pharmaceutical players.
This year’s event has brought together more than 62,000 industry professionals, over 2,400 exhibitors and more than 180 speakers from 160-plus countries and regions, cementing CPHI’s status as the most influential flagship gathering in the global pharmaceutical ingredients and manufacturing value chain.
This year marks Apeloa’s 37th appearance at CPHI, making it one of the earliest Chinese pharmaceutical companies to join the show – and a long-standing witness to the industry’s evolution. At this year’s exhibition, Apeloa highlighted its core strengths in one-stop CDMO services, specialty APIs, formulation products and green process technologies, holding in-depth discussions with multinational pharmaceutical companies and innovative biotech companies from Europe, North America, and the Asia-Pacific regions. These engagements further strengthened the company's global supply chain partnerships and laid a solid foundation for overseas market expansion and project collaboration going forward. 
A global footprint and deep international engagement have long been central to Apeloa's strategy. Beyond CPHI Milan, the company's BD team has taken an active role in leading international industry conferences, including the 2026 SAPA Annual Conference, the 24th San Diego BioPharma Conference, and Discovery on Target. Through these frequent, high-level exchanges, Apeloa stays close to the forefront of global innovation, precisely aligning with the R&D and commercialization needs of overseas partners while steadily enhancing its influence and competitiveness in the global pharmaceutical industry chain.
Looking ahead, Apeloa will pursue innovation and internationalization in tandem, continuously strengthening its R&D capabilities, quality systems, and global delivery network. With a more resilient supply chain and more efficient services, the company aims to integrate more deeply into the global pharmaceutical innovation ecosystem — delivering high-quality, sustainable products and solutions to customers worldwide and showcasing the professional strength and brand image of Apeloa Manufacturing on the international stage.
